ARWR vs SLN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ARWR is the larger of the two ($6.86B market cap): the incumbent the market prices for continued execution (-9.78x forward earnings, beta 1.37). SLN is the smaller challenger ($1.23B), priced similarly on forward earnings (-51.99x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ARWR vs SLN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricARWRSLNWhat it tells you
Market cap$6.86B$1.23BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-9.78-51.99Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.371.34Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range20% of range99% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book14.7624.27How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ARWR and SLN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARWR and SLN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARWR and SLN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Arrowhead Pharmaceuticals (ARWR) do?

Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siRNA) medicines that silence disease-causing genes in the liver and, increasingly, in tissues like the lung and muscle. Its lead drug, plozasiran (marketed as REDEMPLO), targets APOC3 to lower triglycerides and was approved by the U.S. FDA in November 2025 for familial chylomicronemia syndrome (FCS), with additional approvals in China, Canada, Australia, and the European Union. Behind it sits a broad pipeline spanning cardiometabolic disease, obesity, pulmonary, CNS, and muscle targets, several of which are partnered.

Full ARWR guide

What does Silence Therapeutics (SLN) do?

Silence Therapeutics plc is a London-headquartered biotechnology company built around short interfering RNA, a class of drug that switches off the production of a specific disease-causing protein in the liver rather than blocking it after the fact. Its proprietary discovery platform, marketed as mRNAi GOLD, attaches a GalNAc sugar to the siRNA so the molecule is taken up by liver cells, which is the same delivery approach behind the approved RNAi drugs on the market today. Two candidates carry the story. Zerlasiran silences the LPA gene to lower lipoprotein(a), an inherited cardiovascular risk factor with no approved therapy, and produced reductions of more than 80 percent in its Phase 2 ALPACAR-360 trial. Divesiran targets TMPRSS6 to raise hepcidin and control red blood cell production in polycythemia vera, a chronic blood cancer whose patients are otherwise managed with repeated therapeutic phlebotomy. A third asset, SLN312, was returned to Silence in March 2026 after AstraZeneca elected not to advance it past Phase 1.

Full SLN guide

ARWR vs SLN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ARWR drivers: REDEMPLO (plozasiran) launch and label expansion; Partnership economics.
  • SLN drivers: Divesiran after a positive SANRECO Phase 2; A partner for zerlasiran.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. For SLN, silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings.

ARWR or SLN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARWR if you believe its drivers more; SLN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARWR and SLN guides.

ARWR vs SLN: the full fundamentals

ARWR. Arrowhead's reported revenue is dominated by partnership and milestone payments, which makes results swing dramatically between quarters: about $264 million in the December 2025 quarter versus about $75 million in each of the next two, when losses widened. With no positive earnings to anchor a P/E, the market cap of about $8.1 billion (roughly 12 times TTM revenue) reflects the REDEMPLO launch, the pipeline including ARO-MAPT, and future deal flow. The 14 analysts Yahoo Finance tracks have a mean target near $107, well above the October 16 close of $57.42.

SLN. Conventional valuation multiples do not apply: trailing revenue is under $1 million, so price-to-sales (about 890x) and price-to-earnings are arithmetic noise. Adding the roughly $201 million of gross offering proceeds to the $72 million held at June 30 suggests cash in the region of $250 million or more after fees and third-quarter spending, so a roughly $548 million market cap implies the market values divesiran, zerlasiran and the platform at about $300 million. Figures are approximate and as of October 16, 2026; the third-quarter report, expected around November 5 (an estimated date), will show the actual post-raise cash balance.

Headline figures (approximate, October 2026): ARWR shows revenue (ttm) ~$669M, q3 fy2026 revenue (apr-jun 2026) ~$75M, q3 fy2026 net loss ~$194M (EPS -$1.36 vs -$1.23 est.), net income (ttm) ~-$320M; SLN shows market cap ~$548M (at ~$8.81 per ADS, Oct 16, 2026), revenue (ttm) ~$0.6M (collaboration revenue only, down from ~$34M in FY2024), net loss (ttm) ~$60M; Q2 2026 net loss ~$9M, eps per ads (trailing / forward) ~-$1.29 / ~-$0.38.

The bottom line: ARWR vs SLN

ARWR and SLN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARWR and SLN exposure against your real portfolio. It is not an investment adviser.

Wondering how ARWR or SLN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Arrowhead Pharmaceuticals

Ask Walnut's AI anything about ARWR and see how it fits what you own.

FAQ

What is the difference between ARWR and SLN?

+

Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siRNA) medicines that silence disease-causing genes in the liver and, increasingly, in tissues like the lung and muscle. Silence Therapeutics plc is a London-headquartered biotechnology company built around short interfering RNA, a class of drug that switches off the production of a specific disease-causing protein in the liver rather than blocking it after the fact. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ARWR or SLN the better stock?

+

Neither is universally better. ARWR is the larger incumbent; SLN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ARWR or SLN?

+

On forward P/E (as of November 2026), ARWR trades at -9.78x and SLN at -51.99x, so SLN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ARWR and SLN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ARWR vs SLN?

+

ARWR: Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech. ARO-MAPT's tau reductions so far come only from healthy volunteers, and biomarker changes have not yet been shown to slow Alzheimer's disease, a field with a long record of late-stage failures. The stock's swing from a 52-week high of $95.49 to $57.42 in October 2026 shows how much of the valuation rides on sentiment around these catalysts. SLN: Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. The SANRECO Phase 2 succeeded, but Phase 2 results in 48 patients do not guarantee a Phase 3 win, and the planned Phase 3 will take years and consume a large part of the cash raised in August 2026. A partner for zerlasiran may not appear on acceptable economics or at all, which would leave the larger asset stranded. Dilution is no longer hypothetical: the August offering added about 14.9 million ADSs at $13.50, and the stock has since traded well below that price, closing near $8.81 on October 16, 2026 after a 28% fall in a month. Competition is well funded on both fronts: several large pharmaceutical companies are running Phase 3 lipoprotein(a) programs, and polycythemia vera already has approved and late-stage alternatives, including rusfertide aimed at the same hepcidin biology. Because the ADSs represent three ordinary shares each, per-share figures quoted for the Nasdaq listing and the underlying UK share count are not directly comparable, which is a frequent source of confusion when reading coverage.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ARWR or SLN; figures are approximate and dated (as of November 2026). Verify current data before investing.